pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
STAT·58m ago·1 min read
save

Senators say HHS Secretary RFK Jr.’s Gardasil stake explanation contradicts earlier testimony

Aug 25, 2026·read at STAT ↗RegulatoryNegative

A group of U.S. senators have raised concerns about the explanation offered by Robert F. Kennedy Jr., the Health and Human Services secretary, regarding how he disposed of a financial interest tied to litigation over Merck’s Gardasil vaccine.

The senators contend that his recent account conflicts with answers he previously gave in written testimony and in a federal ethics filing.

The dispute centers on potential conflicts of interest and whether the senior official complied with ethical standards while overseeing national health policy.

The issue adds to ongoing scrutiny of vaccine‑related litigation and highlights the political focus on drug pricing and accountability.

source

This writeup was produced by pharmadog from original reporting by STAT.

Original headline: “STAT+: Pharmalittle: We’re reading about RFK Jr. vaccine disclosures, a Merck loss over Medicare prices, and more”

read at STAT ↗
693 words · retrieved 52m ago
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
Ultragenyx Pharmaceutical Inc.3JOHNSON & JOHNSONModerna, Inc.ROCHE
drugs
ObesityRare Diseasenipocalimab
topics
Vaccine8Rare Disease3Approval2Gene Therapy (AAV)2Hematology2ImmunologyObesityOncologymRNA Therapeutic

related stories

  • Dec 22Fierce Biotech Fundraising Tracker '26: Abcuro secures $66M; InduPro assembles $77MFierce Biotech
  • 27m agoCellares cuts jobs after losing pharma customerBioSpace
  • Jun 2910 clinical trials to watch in the second half of 2026BioPharma Dive
  • Dec 23Fierce Biotech Layoff Tracker 2026: Kolon cuts workforce after ph. 3 fail; Sanofi sheds 229 staffersFierce Biotech
  • 1d agoSTAT+: Pharmalittle: We’re reading about Medicaid obesity-drug coverage, a Regenxbio gene therapy, and moreSTAT